Home  |  Contact

Cellosaurus MOLT-4 (CVCL_0013)

Cell line name MOLT-4
Synonyms Molt-4; MOLT 4; Molt 4; MOLT.4; MOLT4; Molt4; GM02219; GM02219C; GM2219C
Accession CVCL_0013
Resource Identification Initiative To cite this cell line use: MOLT-4 (RRID:CVCL_0013)
Comments Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Part of: NCI-60 cancer cell line panel.
Doubling time: 31.56 +- 1.49 hours (PubMed=24762992); 33 hours (PubMed=17117183); 29 hours (PubMed=20922763); 27.9 hours (NCI-DTP); ~40 hours (DSMZ); 24-48 hours (CLS).
Microsatellite instability: Instable (MSI-high) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Peripheral blood.
Sequence variations Heterozygous for NRAS p.Gly12Cys (c.34G>T) (PubMed=17088437).
Homozygous for PTEN p.Lys267fs*9 (c.800delA) (PubMed=17088437).
Heterozygous for STK11 p.Gln214Ter (c.640C>T) (PubMed=17088437).
Heterozygous for TP53 p.Arg306Ter (c.916C>T) (PubMed=17088437).
HLA typing Source: PubMed=15748285
Class I
Class II
Disease Adult T acute lymphoblastic leukemia (NCIt: C9142)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_M771 (M311)CVCL_F827 (MOLT-4 clone 8)CVCL_5J16 (MOLT-4-luc2)
CVCL_2657 (NH17)
Originate from same individual CVCL_0624 ! MOLT-3
Sex of cell Male
Age at sampling 19Y
Category Cancer cell line
STR profile Source(s): ATCC; CLS; COG; Cosmic-CLP; DSMZ; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=19372543; PubMed=20922763; PubMed=25877200

CSF1PO11,12,13 (ATCC; COG; Cosmic-CLP; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
11,12 (CLS; DSMZ)
D3S135815,16 (CLS)
14,16 (KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
D5S81812 (ATCC; CLS; COG; Cosmic-CLP; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
11,12 (DSMZ)
12,13 (PubMed=25877200)
D7S8208,10,11 (ATCC; CLS; COG; Cosmic-CLP; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
8,10 (DSMZ)
D8S11799,13,14 (CLS)
9,14 (COG; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
9,14,15 (PubMed=11416159)
9,13,14,15 (PubMed=25877200)
D13S31712,13 (ATCC; CLS; COG; Cosmic-CLP; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
12,13,14 (DSMZ)
D16S53911,14 (ATCC; CLS; Cosmic-CLP; DSMZ; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
11,14,15 (COG; JCRB; PubMed=25877200)
D18S5112,13,17 (CLS)
13,16,17 (DOI=10.4172/2157-7145.S2-005)
13,17 (PubMed=19372543; PubMed=20922763; PubMed=25877200)
D19S43314,15 (DOI=10.4172/2157-7145.S2-005; PubMed=20922763; PubMed=25877200)
14,15,16 (PubMed=19372543)
D21S1127,28,29,30,31 (COG; DOI=10.4172/2157-7145.S2-005; PubMed=25877200)
28,29,30 (CLS; PubMed=11416159)
28,29,30,31 (PubMed=19372543; PubMed=20922763)
FGA22,24 (CLS)
22,23,24,25 (COG; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
22,25 (PubMed=11416159)
21,22,23,24,25 (PubMed=25877200)
Penta D8,12,13 (CLS)
8,13 (PubMed=25877200)
Penta E14,15,16 (CLS)
14,16 (PubMed=25877200)
vWA17,18 (ATCC; CLS; COG; Cosmic-CLP; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=20922763; PubMed=25877200)
16,17,18 (DSMZ)
17 (PubMed=11416159)
17,18,19 (PubMed=19372543)
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm

PubMed=4567231; DOI=10.1093/jnci/49.3.891
Minowada J., Onuma T., Moore G.E.
Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.
J. Natl. Cancer Inst. 49:891-895(1972)

PubMed=4547172; DOI=10.1093/jnci/53.3.655
Huang C.C., Hou Y., Woods L.K., Moore G.E., Minowada J.
Cytogenetic study of human lymphoid T-cell lines derived from lymphocytic leukemia.
J. Natl. Cancer Inst. 53:655-660(1974)

PubMed=165156; DOI=10.1002/ijc.2910150217
Nilsson K., Ponten J.
Classification and biological nature of established human hematopoietic cell lines.
Int. J. Cancer 15:321-341(1975)

PubMed=6200433; DOI=10.1007/BF00364762
Brodsky F.M.
A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.
Immunogenetics 19:179-194(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

Greenberg J.M., Gonzalez-Sarmiento R., Arthur D.C., Wilkowski C.W., Streifel B.J., Kersey J.H.
Immunophenotypic and cytogenetic analysis of Molt-3 and Molt-4: human T-lymphoid cell lines with rearrangement of chromosome 7.
Blood 72:1755-1760(1988)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=8316623; DOI=10.2307/3578190
Evans H.H., Ricanati M., Horng M.-F., Jiang Q., Mencl J., Olive P.
DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines.
Radiat. Res. 134:307-315(1993)

Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y., Xu B., Einhorn S.
Interferon system defects in malignant T-cells.
Leukemia 8:425-434(1994)

PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x
Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G., Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.
Br. J. Haematol. 91:350-354(1995)

PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x
Borgonovo Brandter L., Heyman M., Rasool O., Liu Y., Grander D., Einhorn S.
p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.
Eur. J. Haematol. 56:313-318(1996)

PubMed=9685479; DOI=10.1093/nar/26.16.3651
Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.
Telomere analysis by fluorescence in situ hybridization and flow cytometry.
Nucleic Acids Res. 26:3651-3656(1998)

PubMed=10071127; DOI=10.1016/S0145-2126(98)00146-5
Kawamura M., Ohnishi H., Guo S.X., Sheng X.M., Minegishi M., Hanada R., Horibe K., Hongo T., Kaneko Y., Bessho F., Yanagisawa M., Sekiya T., Hayashi Y.
Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.
Leuk. Res. 23:115-126(1999)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=11021758; DOI=10.1038/sj.leu.2401891
Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A., Gaulton G.N., Ratajczak M.Z.
Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines.
Leukemia 14:1821-1832(2000)

Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11986953; DOI=10.1038/sj.leu.2402485
O'Donnell P.H., Guo W.-X., Reynolds C.P., Maurer B.J.
N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.
Leukemia 16:902-910(2002)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11-11(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17117183; DOI=10.1038/sj.bjc.6603447
Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J., Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.
Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.
Br. J. Cancer 95:1537-1544(2006)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

Fang R., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20-20(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

Ma X.-C., Liu C.-Y., Sun X.-J., He J.-J., Wan S.-G., Sun W.-L.
Genetic characteristics of human acute lymphoblastic leukemia cell line Molt-4.
Zhongguo Shi Yan Xue Ye Xue Za Zhi 22:280-284(2014)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20-20(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cell line collections ATCC; CRL-1582
BCRC; 60060
BCRJ; 0176
CLS; 300115/p664_MOLT-4
Coriell; GM02219
ECACC; 85011413
ECACC; 94022544
ICLC; HTL99025
JCRB; IFO50362
KCB; KCB 200940YJ
KCLB; 21582
NCBI_Iran; C149
RCB; RCB0206
Cell line databases/resources CLDB; cl3524
CLDB; cl3525
CLDB; cl3527
CLDB; cl3528
CLDB; cl3529
CLDB; cl3530
CLDB; cl3531
CLDB; cl3532
CLDB; cl4976
CLDB; cl5233
CCRID; 3111C0001CCC000043
CCRID; 3131C0001000700037
CCRID; 3131C0001001200018
CCRID; 3142C0001000000079
Cosmic-CLP; 905958
dbMHC; 48976
GDSC; 905958
IHW; IHW09226
IMGT/HLA; 11094
Lonza; 810
Ontologies BTO; BTO:0000873
CLO; CLO_0007825
CLO; CLO_0032246
CLO; CLO_0050992
EFO; EFO_0001220
MCCL; MCC:0000335
Biological sample resources BioSample; SAMN03470847
BioSample; SAMN03471400
BioSample; SAMN03472410
BioSample; SAMN03473319
Chemistry resources ChEMBL-Cells; CHEMBL3307557
ChEMBL-Targets; CHEMBL614177
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM2092
GEO; GSM50196
GEO; GSM50912
GEO; GSM236794
GEO; GSM236830
GEO; GSM750821
GEO; GSM799348
GEO; GSM799411
GEO; GSM887336
GEO; GSM888412
GEO; GSM1181333
GEO; GSM1181349
GEO; GSM1670128
GEO; GSM2124644
Other Wikidata; Q54906365
Polymorphism and mutation databases Cosmic; 716176
Cosmic; 721716
Cosmic; 801730
Cosmic; 850194
Cosmic; 850381
Cosmic; 875865
Cosmic; 897451
Cosmic; 905958
Cosmic; 913409
Cosmic; 919154
Cosmic; 922677
Cosmic; 932766
Cosmic; 933547
Cosmic; 974249
Cosmic; 991545
Cosmic; 999763
Cosmic; 1012099
Cosmic; 1019314
Cosmic; 1044254
Cosmic; 1070704
Cosmic; 1071877
Cosmic; 1082518
Cosmic; 1092615
Cosmic; 1115596
Cosmic; 1118467
Cosmic; 1127263
Cosmic; 1130237
Cosmic; 1151788
Cosmic; 1175131
Cosmic; 1175857
Cosmic; 1176596
Cosmic; 1226858
Cosmic; 1305339
Cosmic; 1312325
Cosmic; 1330500
Cosmic; 1483362
Cosmic; 1509200
Cosmic; 1524808
Cosmic; 1639636
Cosmic; 1664513
Cosmic; 1811158
Cosmic; 1998457
Cosmic; 2039521
Cosmic; 2165720
Cosmic; 2361368
Cosmic; 2602924
Cosmic; 2560251
Proteomic databases PRIDE; PXD005942